Gent, Belgium --(EQS)-- Metrics in Balance (EURONEXT: MLMIB, ISIN BE0974328602), a clinical-diagnosis Company or "Metrics in Balance" or "MIB" or "the Company" is proud to provide investors with an update in the Company's business development.
"The Company has started to sell DNA-kits helping clients achieve a better lifestyle. Together with blood tests we could make a patient's DNA actionable with personalized treatment plans ultimately setting up personalized supplements packages.
Metrics in Balance will be doing this by using a B to B to C business model: we are looking for health professionals that are selling our diagnostic kits to their patients and guide them further in their journey towards a better lifestyle. " - Dirk Verstraete, CEO - Metrics in Balance
Metrics in Balance currently has nine DNA testing coaches at this present time and plans to have fifty by the end of the summer. Ultimately by the end of the year the objective would be to contract 250 coaches by the end of the year. Our vision for our clients is to improve their quality of life through testing and treatment plans on all three levels of health: Structural-biochemical and emotional.
Further diagnostic tests will be added soon (intestinal microbiome, oral microbiome.) and four full-time staff members will join the team in October 2021. This will give us the opportunity to open two new clinics. Starting August 1, 2021 our second clinic in Tilburg will open, it is a multi-disciplinary clinic that will be providing treatment on all three levels of the health triangle (structural-biochemical and emotional).
Contact:
Metrics in Balance NV
Dirk Verstraete
Chief Executive Officer
+32 497 544 558
info@mibmedical.com
www.mibmedical.com
Investor Relations:
Maurus Moser
+41 41 511 23 33
maurus.moser@stscapital.ch
End of Media Release
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.